In the Algerian pharmaceutical market, the supply of life-saving vaccines hinges entirely on a single regulatory gateway: the National Pharmaceutical Products Agency (ANPP). While a vaccine shipment may successfully clear customs, its legal distribution remains strictly prohibited without an official ANPP release certificate. The ANPP holds exclusive authority to approve or refuse any batch, making regulatory compliance the ultimate bottleneck for market access.
Recently, this legal and operational landscape has tightened significantly. With the enforcement of ANPP Note No. 13 in early 2026, the regulatory scrutiny on temperature-sensitive products has intensified. Marketing Authorization Holders and importers are now subject to rigorous cold chain verification, requiring continuous, tamper-proof proof of compliance from the manufacturing floor to the point of receipt. In this environment, a single unjustified temperature deviation or incomplete traceability document can trigger immediate batch rejection, supply chain disruption, and severe administrative sanctions.
This handbook provides a focused overview of the legal framework governing vaccine batch release in Algeria. It examines the mandatory governance structure, the heightened compliance requirements for thermosensitive vaccines, and the legal consequences of non-compliance. More importantly, it outlines the strategic intersection of quality assurance, logistics, and legal counsel required to protect your marketing authorizations and ensure uninterrupted distribution.
